Current and future treatments for Alzheimer's disease.
TLDR
Current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials are discussed.Abstract:
Alzheimer’s dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as ‘disease-modifying’ drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulati...read more
Citations
More filters
Journal ArticleDOI
Editing the Central Nervous System Through CRISPR/Cas9 Systems.
Agustin Cota-Coronado,Néstor Fabián Díaz-Martínez,Eduardo Padilla-Camberos,N. Emmanuel Díaz-Martínez +3 more
TL;DR: Current alternatives to generate systems based on CRISPR/Cas9 that can cross the blood–brain barrier (BBB) and may be used further clinically to improve treatment for neurodegeneration in Parkinson’s and Alzheimer's disease.
Journal ArticleDOI
A simple differentiation protocol for generation of induced pluripotent stem cell-derived basal forebrain-like cholinergic neurons for Alzheimer’s disease and frontotemporal dementia disease modeling
Sonia Sanz Muñoz,Sonia Sanz Muñoz,Martin Engel,Martin Engel,Rachelle Balez,Rachelle Balez,Dzung Do-Ha,Dzung Do-Ha,Mauricio Castro Cabral-da-Silva,Mauricio Castro Cabral-da-Silva,Damián Hernández,Damián Hernández,Tracey Berg,Tracey Berg,Jennifer A. Fifita,Natalie Grima,Shu Yang,Ian P. Blair,Garth A. Nicholson,Anthony L. Cook,Alex W. Hewitt,Alex W. Hewitt,Alex W. Hewitt,Alice Pébay,Alice Pébay,Lezanne Ooi,Lezanne Ooi +26 more
TL;DR: A reliable protocol using only small molecule inhibitors and growth factors, while avoiding transfection or cell sorting methods, is developed to achieve a BFCN culture that expresses the characteristic markers of cholinergic neurons.
Journal ArticleDOI
Comparative Cholinesterase, α-Glucosidase Inhibitory, Antioxidant, Molecular Docking, and Kinetic Studies on Potent Succinimide Derivatives.
Ashfaq Ahmad,Ashfaq Ahmad,Farhat Ullah,Abdul Sadiq,Muhammad Ayaz,Muhammad Saeed Jan,Muhammad Shahid,Abdul Wadood,Fawad Mahmood,Umer Rashid,Riaz Ullah,Muhammad Umar Khayam Sahibzada,Ali S. Alqahtani,Hafiz Majid Mahmood +13 more
TL;DR: Both succinimide derivatives exhibited considerable inhibitory activities against cholinesterases and α-glucosidase enzymes and proved to have antiradical properties.
Journal ArticleDOI
Electric Field Disruption of Amyloid Aggregation: Potential Noninvasive Therapy for Alzheimer’s Disease
Jahnu Saikia,Gaurav Pandey,Sajitha Sasidharan,Ferrin Antony,Harshal B. Nemade,Sachin Kumar,Nitin Chaudhary,Vibin Ramakrishnan +7 more
TL;DR: This study experimentally investigates the influence of the external electric field (EF) and magnetic field (MF) of varying strengths on the in vitro fibrillogenesis of hydrophobic core sequence, A β16-22, and its parent peptide, Aβ1-42 and provides a scientific roadmap for future noninvasive, therapeutic solutions for the treatment of Alzheimer's disease.
Journal ArticleDOI
Viral Involvement in Alzheimer's Disease.
TL;DR: In this article, the authors discuss the potential role of HSV-1 in Alzheimer's disease and argue for further studies to investigate this relationship and argue that valacyclovir has shown patient improvement in cognition compared to controls in AD clinical studies.
References
More filters
Journal ArticleDOI
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling,Paul S. Aisen,Laurel A. Beckett,David A. Bennett,Suzanne Craft,Anne M. Fagan,Takeshi Iwatsubo,Clifford R. Jack,Jeffrey Kaye,Thomas J. Montine,Denise C. Park,Eric M. Reiman,Christopher C. Rowe,Eric Siemers,Yaakov Stern,Kristine Yaffe,Maria C. Carrillo,Bill Thies,Marcelle Morrison-Bogorad,Molly V. Wagster,Creighton H. Phelps +20 more
TL;DR: A conceptual framework and operational research criteria are proposed, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies and it is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD.
Journal ArticleDOI
The Cholinergic Hypothesis of Geriatric Memory Dysfunction
Raymond T. Bartus,Raymond T. Bartus,Reginald L. Dean,Bernard Beer,Bernard Beer,Arnold S. Lippa,Arnold S. Lippa +6 more
TL;DR: Biochemical, electrophysiological, and pharmacological evidence supporting a role for cholinergic dysfunction in age-related memory disturbances is critically reviewed and an attempt has been made to identify pseudoissues, resolve certain controversies, and clarify misconceptions that have occurred in the literature.
Journal ArticleDOI
Global prevalence of dementia: a Delphi consensus study
Cleusa P. Ferri,Martin Prince,Carol Brayne,Henry Brodaty,Laura Fratiglioni,Mary Ganguli,Kathleen S. Hall,Kazuo Hasegawa,Hugh C. Hendrie,Yueqin Huang,Anthony F. Jorm,Colin Mathers,Paulo Rossi Menezes,Elizabeth Rimmer,Marcia Scazufca +14 more
TL;DR: Detailed estimates of dementia prevalence for each world region are believed to constitute the best currently available basis for policymaking, planning, and allocation of health and welfare resources.
Journal ArticleDOI
Revising the definition of Alzheimer's disease: a new lexicon.
Bruno Dubois,Howard Feldman,Howard Feldman,Howard Feldman,Claudia Jacova,Jeffrey L. Cummings,Steven T. DeKosky,Pascale Barberger-Gateau,André Delacourte,Giovanni B. Frisoni,Nick C. Fox,Douglas Galasko,Serge Gauthier,Harald Hampel,Gregory A. Jicha,Kenichi Meguro,John T. O'Brien,Florence Pasquier,Philippe Robert,Martin N. Rossor,Steven Salloway,Marie Sarazin,Leonardo Cruz de Souza,Yaakov Stern,Pieter Jelle Visser,Pieter Jelle Visser,Philip Scheltens +26 more
TL;DR: This paper aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities.
Journal ArticleDOI
Statins and the risk of dementia.
Hershel Jick,Gwen L. Zornberg,Gwen L. Zornberg,Susan S. Jick,Sudha Seshadri,David A. Drachman +5 more
TL;DR: Individuals of 50 years and older who were prescribed statins had a substantially lowered risk of developing dementia, independent of the presence or absence of untreated hyperlipidaemia, or exposure to nonstatin LLAs.
Related Papers (5)
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
John Hardy,Dennis J. Selkoe +1 more
Neuroinflammation in Alzheimer's disease
Michael T. Heneka,Monica J. Carson,Joseph El Khoury,Gary E. Landreth,Frederic Brosseron,Douglas L. Feinstein,Andreas H. Jacobs,Tony Wyss-Coray,Tony Wyss-Coray,Javier Vitorica,Richard M. Ransohoff,Karl Herrup,Sally A. Frautschy,Bente Finsen,Guy C. Brown,Alexei Verkhratsky,Alexei Verkhratsky,Alexei Verkhratsky,Koji Yamanaka,Jari Koistinaho,Eicke Latz,Eicke Latz,Annett Halle,Gabor C. Petzold,Terrence Town,Dave Morgan,Mari L. Shinohara,V. Hugh Perry,Clive Holmes,Clive Holmes,Nicolas G. Bazan,David J. Brooks,Stéphane Hunot,Bertrand Joseph,Nikolaus Deigendesch,Olga Garaschuk,Erik Boddeke,Charles A. Dinarello,John C.S. Breitner,Greg M. Cole,Douglas T. Golenbock,Markus P. Kummer +41 more